Cara Therapeutics Income After Taxes 2012-2024 | CARA

Cara Therapeutics income after taxes from 2012 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.

Cara Therapeutics Income After Taxes 2012-2024 | CARA

Cara Therapeutics income after taxes from 2012 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.5B
Vertex Pharmaceuticals (VRTX)$119.5B
Regeneron Pharmaceuticals (REGN)$114.6B
Gilead Sciences (GILD)$103.4B
Bristol Myers Squibb (BMY)$101.6B
CSL (CSLLY)$97.4B
GSK (GSK)$84.8B
Alnylam Pharmaceuticals (ALNY)$35.2B
Argenex SE (ARGX)$31.4B
Biogen (BIIB)$28.2B
BioNTech SE (BNTX)$28B
Moderna (MRNA)$24.6B
Illumina (ILMN)$21.1B
BeiGene (BGNE)$20.7B
Genmab (GMAB)$16B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.6B
Incyte (INCY)$12.5B
Insmed (INSM)$12.5B
Vaxcyte (PCVX)$12.4B
Bio-Techne Corp (TECH)$12.4B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Ascendis Pharma (ASND)$8.6B
Roivant Sciences (ROIV)$8.6B
Legend Biotech (LEGN)$8.5B
Repligen (RGEN)$8.2B
Intra-Cellular Therapies (ITCI)$7.7B
Exelixis (EXEL)$7.5B